Brief: Hanall's Licensed Partner In China Enters Sublicense Agreement With Cspc To Further Accelerate Development Of Batoclimab
11/10/2022 12:58
Oct 11 (Reuters) - Hanall Biopharma Co Ltd 009420.KS :
* HANALL'S LICENSED PARTNER IN CHINA ENTERS SUBLICENSE
AGREEMENT
WITH CSPC TO FURTHER ACCELERATE DEVELOPMENT OF BATOCLIMAB
Source text for Eikon: ID:nPny14v1a
Further company coverage: 009420.KS
Recent news on Hanall Biopharma
See all newsQ2 2026 Operating Profit Up 567.4% QoQ, 388.5% YoY To Won 5.60 Billion
Brief: Hanall Biopharma Co Icc Rules Licensing Deal With Harbour Biomed Continues To Be Effective
Brief: Hanall Biopharma Q1 Operating Profit 839 Million Won, Swings To Profit From Year Earlier
Immunovant falls as drug for thyroid eye disease fails late-stage trials
Immunovant falls as eye disease therapy fails in late-stage studies